论文部分内容阅读
以砷酸(ATO)为对照,研究雄黄微生物溶解液(RBS)的药物动力学行为,探索雄黄溶解后,其中砷在大鼠体内吸收和分布的变化规律。以砷酸(腹腔注射,含砷量0.3mg·kg?1)为对照组,雄黄微生物溶解液(腹腔注射,含砷量0.3mg·kg?1)为给药组,测定药物中砷在大鼠血液中的浓度及在心、肝、脾、肺、肾和脑等组织中的浓度,并研究药代动力学参数的变化。RBS组药代动力学参数与ATO组接近,其中砷在大鼠各组织中蓄积量大幅度降低,与对照组相比具有显著差异。雄黄经生物溶解后,以无机砷或有机砷的形式存在,与对照组相比,砷的形态成分发生明显变化,药物生物利用度明显提高,砷在组织中几乎没有蓄积。这一结果可能为微生物技术在研究、开发雄黄的应用提供有力依据。
Arsenic acid (ATO) was used as a control to study the pharmacokinetics of realgar’s solution (RBS), and to explore the variation of absorption and distribution of arsenic in rats after dissolution of realgar. Arsenic acid (intraperitoneal injection, arsenic content of 0.3mg · kg -1) as the control group, realgar microbiological solution (intraperitoneal injection, arsenic content of 0.3mg · kg? 1) for the administration group, the determination of arsenic in the drug Concentration of rat blood and its concentration in heart, liver, spleen, lung, kidney and brain tissues, and study pharmacokinetic parameters. The pharmacokinetic parameters of RBS group were similar to that of ATO group, and the accumulation of arsenic in various tissues of rats was significantly reduced, which was significantly different from that of control group. When the realgar was dissolved by organism, it was in the form of inorganic arsenic or organic arsenic. Compared with the control group, the morphological changes of arsenic obviously changed, the bioavailability of the drug increased obviously, and arsenic accumulated little in the tissue. This result may provide a strong basis for the application of micro-organisms in the research and development of realgar.